science

plenary session

plenary

academic

We’re in an era of big data - and hospitals and GPs are generating an inordinate amount of it that has potential to improve everyone’s health. But only if it’s used properly. New research published on www.bmj.com this week describes another set of information, about that data, that the authors believe could be just as important as the data itself.

Griffin weber, and Isaac Kohane, from the Department of Biomedical informatics at Harvard medical school join us to discuss.

Read the full research:
https://www.bmj.com/content/361/bmj.k1479

Big Metadata

Join us for an introduction to who we are and what our podcast is about, then stick around for a hard-hitting discussion of evidence-based medicine, randomized controlled trials, sham controls, and broad next-generation sequencing in cancer. Our guest is Adam Obley, an Assistant Professor of Medicine at Oregon Health & Science University.

1.01: Introduction and Dr. Adam Obley

In episode 2, we discuss the fellowship program and then take a deep dive into hype surrounding cancer drugs. Our guest is Jeremy Cetnar, MD from Oregon Health & Science University.

1.02: HemOnc Fellowship and Hype in Cancer Medicine with Dr. Jeremy Cetnar

We're moving to our new format. We begin with a monologue of the most noteworthy articles in this week's news. We'll be talking about real-world evidence, Right to Try, talazoparib, and the FDA approval for nivolumab in small-cell lung cancer. In the second half of the show, we'll interview Dr. Andrae Vandross, a community oncologist at UCLA Medical Center.

August 2018

1.03: RWE, Right to Try, Talazoparib, Nivolumab, and Dr. Andrae Vandross

This week's episode is on nutritional epidemiology by JPA Ioannidis; lenvatinib for hepatocellular carcinoma; nivolumab and ipilimumab for melanoma; and #medtwitter with Dr. Avi O Glasser from OHSU.

1.04: Nutritional Epi, Lenvatinib, Nivo and Ipi for Melanoma, and Dr. Avi O'Glasser

In this episode we cover the cost and efficacy of cancer drugs; review ECHELON-1; interview Dr. Derrick Tao of OHSU about his recent Lancet Oncology paper on poor control arms; and discuss evidence-based medicine with EBM expert and internist at OHSU, Dr. Martha Gerrity.

September 2018

1.05 Cost and Efficacy of Cancer Drugs, ECHELON-1, Dr. Derrick Tao, and EBM with Dr. Martha Gerrity

This week we open with a critical take on our current system of disseminating scientific research, specifically focusing on the prevalence of -- and dependence on -- medical writers. In the second half of the episode, we interview Dr. Allen Pannell of the Haslam College of Business at the University of Tennessee on using a Frequentist approach vs a Bayesian approach in the context of a single clinical trial. 

Frequentist vs Bayesian: doi.org/10.1136/bmjopen-2018-024256
Dr. Pannell's breast cancer support group: https://www.breastconnect.org/
Dr. Pannell's research project: http://tinyurl.com/peerErPrHer2

Back us on Patreon! www.patreon.com/plenarysession

June 2019

1.66 Employing Medical Writers & Frequentist vs Bayesian Methods with Dr. Allen Pannell

We're back with more questions of the week! Our first question, from Ian Straehley, is inspired by the USMLE Step 2 CK; our second question, from Audrey Tran, is on deciding on a medical specialty. We end the episode with an interview with Dr. Frank Harrell of Vanderbilt University on the Bayesian approach to statistical thinking.

Back us on Patreon! www.patreon.com/plenarysession

August 2019

2.06 Heart Failure, Choosing a Specialty, & the Bayesian Approach with Dr. Frank Harrell

This week we answer a few questions: the first is from Patreon backer, Harry Hong, on Kaplan-Meier curves. The second is from a student at Mount Sinai Medical School who reached out with some ethical questions they had after the ASH annual meeting on the obligations and responsibilities of peer reviewers. Finally, we end the episode with an interview with Dr. Bishal Gyawali of Queens University in Kingston, Ontario, Canada on his new paper out today in the Journal of the National Comprehensive Cancer Network titled "Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials". 

Durations of Response: doi.org/10.6004/jnccn.2019.7345

Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635

Back us on Patreon! www.patreon.com/plenarysession

January 2020

2.31 Listener Questions, Responsibility of Reviewers, & Duration of Response with Dr. Bishal Gyawali

In Episode 04, Uzair speaks with Dr. Atif Mian about why Pakistan keeps going back to the IMF, why the country’s economy keeps going from one crisis to another, and what he would do if he was the economic czar in the country.

Tabadlab Presents...

Pakistonomy - Episode 04 - Atif Mian

This week we discuss management of COVID-19 in the intensive care unit with Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University. We discuss medications, PPE, ventilators, and more!

Back us on Patreon! www.patreon.com/plenarysession

March 2020

2.44 ICU Management of COVID-19 with Dr. Benjamin Singer

This week we discuss several recent articles on the novel coronavirus (SARS-CoV-2) and COVID-19, specifically Dr. Siddhartha Mukherjee's article on the history and science of humanity's history with viruses, Dr. Ezekiel Emanuel's essay on how to fairly allocate dwindling medical resources during this global pandemic, and Dr. John Ioannidis's article on the "evidence fiasco" that has been our response to COVID-19. We end the episode with a Classical Hematology Chat with Drs. Sven Olson and Joseph Shatzel.

Dr. Mukherjee's article: https://www.newyorker.com/magazine/2020/04/06/how-does-the-coronavirus-behave-inside-a-patient
Allocation of Medical Resources: doi.org/10.1056/NEJMsb2005114
Dr. Ioannidis's article: https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/

Back us on Patreon! www.patreon.com/plenarysession

April 2020

2.45 Viral Spread of SARS-CoV-2, Rationing Resources, "Evidence Fiasco", & Classical Hematology Chat

This week we have a far-reaching monologue on COVID-19 and how people are reacting to the public health recommendations concerning COVID-19 (such as cancelling conferences and school, maintaining 6+ feet of distance, wearing cloth masks). We end with an insightful interview with Dr. Venk Murthy on polygenic risk score and, at the end, a bit about how the world of science is failing to combat hype.

Back us on Patreon! www.patreon.com/plenarysession

2.46 Psychology Unearthed by COVID-19 Precautions & Polygenic Risk Score with Dr. Venk Murthy

This week we start with an in-depth monologue on various new developments surrounding COVID-19, specifically the new study in NEJM on the compassionate use of remdesivir as well as the CDC's advice for the general public to wear cloth masks. We end with an interview with Dr. Ameet Sarpatwari of Harvard Medical School on how to create a more effective pharmaceutical system, the CREATES Act of 2019, developing fair and equitable drugs to treat COVID-19, and how to create a just system that balances the need for innovation with the need for access. Dr. Ameet Sarpatwari is the Assistant Director of PORTAL.

Compassionate Use of Remdesivir: doi.org/10.1056/NEJMoa2007016
U.S. Gene Therapy Trials: doi.org/10.1001/jama.2019.22214
NIH Fair Pricing Condition: doi.org/10.7326/M19-2576

Back us on Patreon! www.patreon.com/plenarysession

2.47 Remdesivir, Cloth Masks, & Incentives for COVID-19 Drug Development with Dr. Ameet Sarpatwari

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

2.06 Heart Failure, Choosing a Specialty, & the Bayesian Approach with Dr. Frank Harrell

Plenary Session - inactive due to federal service